Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA Approved for Maintenance Treatment of Patients with Severe Asthma

Documenti analoghi

• Cosentyx (Secukinumab): First IL-17A Antagonist Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis
  di: Fala, Loretta
  Pubblicazione: (2016)
• Mepolizumab (Nucala) For Severe Eosinophilic Asthma
  di: Choy, Min Sung, et al.
  Pubblicazione: (2016)
• Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non–Small-Cell Lung Cancer
  di: Fala, Loretta
  Pubblicazione: (2016)
• Zontivity (Vorapaxar), First-in-Class PAR-1 Antagonist, Receives FDA Approval for Risk Reduction of Heart Attack, Stroke, and Cardiovascular Death
  di: Fala, Loretta
  Pubblicazione: (2015)
• Corlanor (Ivabradine), First HCN Channel Blocker, FDA Approved for the Treatment of Patients with Heart Failure
  di: Fala, Loretta
  Pubblicazione: (2016)